Rethinking Penicillin Allergy: A Diagnostic Label with Lasting Impact

Many patients carry a penicillin allergy label—but most of them are not truly allergic. In fact, up to 90% of people who report a penicillin allergy can actually tolerate it. This widespread mislabeling has serious consequences: it drives the use of less effective, broader-spectrum antibiotics, increases healthcare costs, and contributes to antimicrobial resistance.

Why is penicillin allergy overdiagnosed?

Penicillin allergy is often diagnosed early in life, frequently based on vague or non-specific symptoms like rash, nausea, or vomiting. In many cases, the reaction was not allergic at all—it may have been due to a viral infection or simply misattributed. Over time, these early diagnoses persist in medical records, rarely challenged or re-evaluated. Importantly, even in patients who once had a true allergic reaction, allergy to penicillin tends to wane with time. After ten years, about 80% of patients lose their sensitivity. Yet the allergy label often stays with the patient for life, affecting every antibiotic decision that follows.

The consequences of a false allergy label

Labeling someone as allergic to penicillin limits first-line treatment options. Physicians may resort to alternatives like fluoroquinolones or vancomycin, which are broader-spectrum, more toxic, or less effective. According to the authors, this leads to:

• Longer hospital stays
• Higher rates of treatment failure
• Increased risk of antibiotic-resistant infections
• Higher healthcare costs

For example, patients labeled as penicillin-allergic have been shown to be at significantly higher risk of Clostridium difficile and MRSA infections—two dangerous, hospital-acquired pathogens—due to unnecessary use of second-line antibiotics. Visual manifestations of immediate allergic reactions vary widely—from transient wheals or hives, as seen in the left image, to severe skin involvement with blistering and desquamation, as shown in the right image. These presentations highlight the spectrum of true IgE-mediated responses, which must be clearly distinguished from non-allergic drug side effects.

The case for re-evaluating penicillin allergy

Blumenthal et al. make a strong case for systematic allergy testing, particularly in high-risk populations such as hospitalized patients or those requiring frequent antibiotics. At Bioherent, we believe precision starts with the right diagnosis. Improving how we diagnose and document drug allergies—especially to beta-lactams like penicillin—is essential for building a more rational and sustainable approach to antimicrobial use. At Bioherent, we are developing advanced in vitro diagnostic tools and biomarker-driven solutions to help distinguish true allergies from false positives. By combining nanotechnology, immunochemistry, and biosensor innovation, our goal is to make drug allergy testing safer, faster, and more accessible—ensuring patients receive the right treatment, at the right time.

Reference:

Blumenthal, K.G., Peter, J.G., Trubiano, J.A., & Phillips, E.J. (2019). Antibiotic allergy. JAMA, 321(2), 188–199. https://doi.org/10.1001/jama.2018.19283